Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag

Egis Gyogyszergyar Zrt.

Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag

Egis Gyogyszergyar Nyilvanosan Muekoedoe

Egis Gyogyszergynar Nyilvanosan Muekoedoe Reszvenytarsasag

Balazs Volk

Jozsef Barkoczy

Gyula Simig

Gyula Lukacs

Kalman Nagy

Ferenc Lorant Bartha

Laszlo Pongo

Adrienn Keszthelyi

Andras Dancso

Eva Sipos

Maria Tothne Lauritz

Gyorgyi Kovanyine Lax

Gyorgy Ruzsics

Gyorgy Krasznai

Gyoergy Ruzsics

Tibor Szabo

Gabor Nemeth

Zoltán Varga

László Szlávik

Istvan Ling

Enikó Molnár

Janos Imre

Eva Szabo

Balazs Havasi

Janos Petho

Imre Kiraly

Andras Boza

Jozsef Debreczeni

Gyoergyi Kovanyine Lax

Gabor Gigler

Istvan Gacsalyi

Márta Porcs-Makkay

Krisztina Móricz

Ferenc Jurak

Zsuzsanna Szent-Királlyi

Attila Virág

Tamás Gregor

Mátyás Milen

András Mravik

Imre Kapui

Éva Pécsi

Imre Markovits

Gyoergy Clementis

Judit Broda

Angéla Pandur

Ferenc Antoni

Peter Slegel

Krisztina Fodorné Kocsmár

Laszlo Jozsef Hegedus

Adrienn Karasz

Gabor Laszlo Kapus

Maria Julia Taborine Toth

Judit Halasz

Csaba Hamori

Marta Porcs-makkay

Agnes Kenez

Zsolt Runge

Katalin Kataine Fadgyas

Monika Mezovari

Ferenc Bertha

Maria Kovacs

Lax Gyorgyi Kovanyine

Gyorgy Jeges

Imre Koehegyi

Agnes Angyalne Pataki

Peter Gregor

Balazs Peregi

Jeno Peter Seres

Gyorgy Morovjan

Gabor Bagyinszki

Adrienn Palvolgyi

Ede Laszlo Marvanyos

Balazs Mihalik

Gyoergy Morovjan

Gyoergy Krasznai

Valeria Hoffmanne Fekete

The present invention relates a new process for the preparation of ozanimod of the formula and acid addition salts, via new intermediates and a new polimop form of ozanimod base.

Process for the production of ozanimod

The invention relates to normal or acidic salts of dasatinib and the hydrate and solvate forms thereof. More specifically the invention concerns: dasatinib cyclamic acid salt, dasatinib cyclamic acid (1:1) salt Form I, dasatinib cyclamic acid (1:1) salt Form II, dasatinib hydrogen bromide (1:2) salt, dasatinib methane sulfonic acid (1:2) salt, dasatinib p-toluenesulfonic acid (1:1) dihydrate salt, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form I, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form II, dasatinib p-toluenesulfonic acid (1:1) salt methanol solvate. Moreover the invention relates process for preparing dasatinib salts, pharmaceutical compositions comprising thereof and the use of dasatinib salts the treatment of cancer.

Dasatinib salts

Compounds of formula (I) having a selective dual action on the central GABAergic system, and a process for their preparation and to pharmaceutical compositions containing them.

Dihydro-oxazinobenzodiazepine compounds, a process for their preparation and pharmaceutical compositions containing them

The invention relates to an improved process for the preparation of pharmaceutical active ingredients and also to high purity salts and pharmaceutical compositions prepared by said process. More particularly the invention relates to an economical process for the preparation of the compound having the international non-proprietary name (INN) vortioxetine and the chemical nomenclature 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine. Vortioxetine corresponds to the following Formula  Still more particularly the invention relates to the preparation of high purity vortioxetine L-(+)-mandelate salt of the Formula IX, the conversion of this salt into other highly pure salts and also to the formulation of said salts.

Process for the preparation of vortioxetine salts

The invention relates to a process for the preparation of 5-chloro-N-({(5-S)-2-oxo3-[4-(3-oxo-morj)holine-4-yl)-phenyl]-1,3-oxazolidine-5-yl}-methyl) thiophen-2-carboxamide having the INN rivaroxaban. The invention also relates to intermediates formed in the above process.

Process for the preparation of a rivaroxaban and intermediates formed in said process

The present invention is related to crystalline forms of rosuvastatin zinc (2:1) salt. The polymorphs are suitable for use as pharmaceutically active ingredients in the treatment of the diseases of the lipid metabolism including hypercholesterolemia, hyperlipidemia, dyslipidemia or atherosclerosis. 

Crystalline pharmaceutically active ingredients

The present invention relates to a process for the preparation of dabigatran etexilate of the formula 

Pharmaceutical intermediates and process for the preparation thereof

The present invention is related to intermediates useful in the preparation of pharmaceutically acceptable salts of (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-(3R,5S)-dihydroxy-hept-6-enoic acid and polymorphs of said intermediates, methods for preparation thereof and use thereof.

Method for the preparation of high-purity pharmaceutical intermediates

The present invention is related to methods for the preparation of pharmaceutically acceptable salts of (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-(3R,5S,6E)-dihydroxy-hept-6-enoic acid, intermediates thereof and methods for producing said intermediates.

Method for preparing rosuvastatin salts

The present invention relates to crystalline Form I rosuvastatin zinc (2:1) salt, method of preparation thereof and use thereof as pharmaceutically active ingredient for the treatment of diseases related to lipid metabolism including hyperlipoproteinemia, hypercholesteremia, dyslipidemia and atherosclerosis.

Crystalline form I rosuvastatin zinc salt

The present invention relates to the use of novel vildagliptin complexes for the manufacture of high purity vildagliptin of Formula I and/or pharmaceutical acceptable salts thereof. Further objects of the present invention are pharmaceutically acceptable complexes of vildagliptin and/or amorphous and crystalline forms, anhydrous forms, amorphous and crystalline hydrates, amorphous and crystalline solvates of the complexes and a process for the preparation thereof. Another object of the present invention is the high purity vildagliptin and pharmaceutically acceptable salts thereof prepared form the vildagliptin complexes of the present invention, a process for the preparation thereof and pharmaceutical compositions containing vildagliptin base, pharmaceutically acceptable salts and/or complexes and use thereof for the treatment of type 2 diabetes (NIDDM). The present invention provides pharmaceutically advantageous high purity vildagliptin complexes.

Inorganic salt complexes of vildagliptin

The present invention relates to a new process for the preparation of rosuvastatin [7-[4-(4-Fluorophenyl)-6-isopropyl-2-(methanesulphonyl-methyl-amino)-pyrimidin-5-yl]-(3R,51S)-dihydroxy-hept-6-enoic acid] of the formula (I) salts formed with bivalent cations, preferably with calcium or zinc ions, characterized in that rosuvastatin tert.-butylammonium salt is reacted with the appropriate bivalent cation, preferably with calcium or zinc ions in a mixture of a water immiscible or slightly miscible organic solvent and water and the formed salt is isolated. 

Process for the preparation of rosuvastatin salts

Growing community of inventors

Budapest, Hungary

Balazs Volk